A deep, or lenticulostriate, infarct is a tiny area of dead brain tissue caused by the blockage of one or more lenticulostriate arteries—small penetrating branches that rise almost at right-angles from the stem of the middle cerebral artery (MCA) and dive straight into the deep gray and white matter. Because they irrigate the internal capsule, basal ganglia and adjacent corona radiata, even a pin-head–sized clot can switch off the body’s main motor or sensory cables in an instant. These strokes belong to the wider family of lacunar or small-vessel strokes, typically ≤ 15 mm on MRI. They are common (roughly 20–25 % of all ischaemic strokes) and classically spare the cortex, so they do not produce aphasia, neglect or visual field cuts that larger MCA strokes cause. Their clinical picture is sometimes called the “middle cerebral artery deep syndrome.” ncbi.nlm.nih.govncbi.nlm.nih.gov
A deep (lenticulostriate) infarct is a tiny but strategically important stroke inside the basal ganglia or internal capsule—areas supplied by the lenticulostriate perforators that branch off the first segment (M1) of the MCA. Because these arteries are “end-arteries” with no back-up routes, even a pin-head clot can silence motor and sensory relay lines, leading to weakness, clumsy hands, or pure sensory loss on one side of the body. When larger or multiple MCA branches are blocked, the picture broadens into the classic MCA syndrome: face-arm > leg weakness, loss of sensation, gaze deviation toward the injured hemisphere, aphasia (if the dominant side is hit) or neglect (if the non-dominant side is hit). pubmed.ncbi.nlm.nih.govncbi.nlm.nih.gov
Pathophysiology
Small-vessel wear-and-tear. Years of high blood pressure, diabetes and cholesterol roughen the delicate inner lining of the lenticulostriate arteries. Fat-laden foam cells collect, the wall thickens, and the lumen narrows (lipohyalinosis).
Branch atheromatous disease (BAD). A fatty plaque forms in the parent MCA precisely where a lenticulostriate branch originates. The plaque’s shoulder juts out and chokes the branch like a kinked straw.
Micro-emboli. Sometimes a clot flecks off distant sites (heart, carotid plaque) but is so small that it lodges only in these perforators.
Sudden drops in blood pressure. Deep arteries have few collaterals, so even brief low flow can kill tissue.
Regardless of mechanism, blood flow stops, energy fails, sodium–calcium floods cells, and within minutes neurons die, creating a little crater—a lacune.
Types
Pure lacunar infarct (classical). Single, small cavity ≤ 15 mm, usually from lipohyalinosis.
Branch atheromatous infarct. Elongated lesion ≥15 mm, hugging the course of a lenticulostriate branch and often extending to the surface of the internal capsule—linked to parent-artery plaque.
Multiple lacunes (“lacune cluster”). Numerous scattered holes, the sign of chronic small-vessel disease.
Strategic lacune. A single punch-hole in a “strategic” spot (e.g., anterior limb internal capsule) that triggers striking symptoms such as pure motor stroke.
Subcortical vascular dementia pattern. Tens to hundreds of old lacunes with diffuse white-matter change producing cognitive slowing.
New MRI techniques such as 7-Tesla MRA can now visualise individual lenticulostriate arteries and classify these types more accurately. sciencedirect.com
Common causes
Long-standing high blood pressure. Constant pressure batters the perforator walls, leading to thickening and eventual blockage. It remains the single biggest culprit. my.clevelandclinic.org
Type 2 diabetes mellitus. High glucose cross-links proteins, stiffens arteries and accelerates atherosclerosis.
High LDL cholesterol. Surplus “bad” cholesterol seeds fatty streaks and parent-artery plaques.
Cigarette smoking. Toxins inflame the endothelium, promote clotting and shrink the lumen.
Obesity & metabolic syndrome. Central fat perpetuates insulin resistance, dyslipidaemia and low-grade inflammation.
Chronic kidney disease. Uraemic toxins and anaemia strain small vessels and raise blood pressure.
Obstructive sleep apnoea. Repetitive nocturnal desaturations induce oxidative stress and hypertension spikes.
Small-vessel lipohyalinosis. A histopathological process where fibrinoid material replaces smooth muscle, unique to tiny penetrating arteries.
Branch atheromatous disease (BAD). Local plaque at the MCA origin of a perforator pinches it off. ahajournals.org
Atrial-fibrillation micro-emboli. Though most emboli cause large-artery strokes, the very small shards can lodge in perforators.
Primary CNS vasculitis. Immune attack inflames vessel walls, narrowing them.
Systemic lupus erythematosus or antiphospholipid syndrome. Auto-antibodies trigger clotting in small cerebral arterioles.
Cerebral amyloid angiopathy. β-amyloid deposition weakens small vessels and can thrombose or bleed.
Moyamoya disease. Progressive stenosis of distal ICA/MCA encourages fragile collaterals, but perforators may thrombose first.
Genetic small-vessel disorders (e.g., CADASIL). NOTCH3 mutations thicken arterial media, causing recurrent lacunes in young adults.
Cocaine or amphetamine abuse. Sudden surges in blood pressure provoke perforator rupture or blockage.
Radiation-induced vasculopathy. Cranial irradiation scars and narrows the tiny arterial branches years later.
Severe dehydration or hypotension. Low volume slashes perfusion in the end-arteries with no back-up supply.
Septic micro-emboli (endocarditis). Bacterial clumps shower the brain; the smallest plug perforators.
COVID-19-associated coagulopathy. Hyper-clotting state favours micro-thrombi in the lenticulostriate territory.
Symptoms
Pure motor hemiparesis. Sudden weakness of face, arm and leg on one side with no sensory loss—the internal capsule’s motor fibres are unplugged. physio-pedia.comstanfordmedicine25.stanford.edu
Pure sensory stroke. Numbness and tingling on one side because the thalamic relay is silenced.
Sensorimotor stroke. A mix of weakness and numbness when the infarct straddles motor and sensory tracts.
Dysarthria–clumsy-hand syndrome. Slurred speech plus awkward fine finger movement from a tiny ventral pons or internal capsule lacune.
Ataxic hemiparesis. Weakness mixed with jerky, discoordinated limb due to interruption of fronto-pontine fibres.
Facial droop. The lower half of one side of the face sags; often first sign spotted by family.
Slurred speech (dysarthria). Speech sounds “thick” because facial and tongue muscles lag, though comprehension stays intact.
Loss of fine motor control. Buttoning a shirt or writing suddenly becomes impossible with the affected hand.
Hemichorea or hemiballismus. A deep basal-ganglia lacune can unleash wild flinging movements on one side.
Mild cognitive slowing. Repeated lacunes blunt processing speed and executive function.
Emotional lability. Patients may cry or laugh involuntarily (pseudobulbar affect) when internal capsule fibres are hit.
Transient facial–arm numbness. A warning “lacunar TIA” that often precedes a completed stroke.
Blurring of vision (rare). If optic radiations are brushed, partial visual fuzziness can appear.
Gait imbalance. The leg drags or wobbles, forcing use of a stick.
Difficulty swallowing (dysphagia). Subtle, but coughing on drinks can hint at brainstem extension.
Crippling fatigue. Post-stroke energy drain is common even after tiny infarcts.
Sudden headache. Usually mild; rules out haemorrhage if absent, but may still accompany ischaemia.
Vertigo or dizziness. Rare for pure lenticulostriate stroke but possible if there is concurrent small posterior circulation involvement.
Urgency to pass urine. Disruption of frontal-pontine inhibitory pathways lets bladder reflexes run free.
Post-stroke depression. Biological and psychosocial factors combine, appearing weeks after the event.
Diagnostic tests
A. Physical-examination bedside tests
Vital-sign check. Blood pressure, pulse, temperature and oxygen saturation give rapid clues to triggers like hypertension or infection.
FAST stroke screen. Face droop, Arm weakness, Speech slurring, Time of onset—simple cues for immediate referral.
NIH Stroke Scale. A 15-item scoring sheet quantifies severity and guides thrombolysis decisions.
Cranial-nerve exam. Tests eye movements, facial strength and swallow, pinpointing subcortical vs cortical hits.
Manual muscle testing. Grading 0-5 strength maps the precise hemiparesis pattern.
Pin-prick and light-touch exam. Distinguishes pure motor from sensory-involved lacunes.
Deep-tendon reflexes. Brisk reflexes and a Babinski sign reveal upper-motor-neuron damage.
Gait assessment. Watching the patient walk exposes hemiplegic or ataxic patterns invisible in bed.
B. Simple manual/bedside manoeuvres
Finger-to-nose test. Overshoot or tremor signals cerebellar pathway involvement.
Heel-to-shin run. Highlights ataxic hemiparesis when the leg zig-zags.
Pronator-drift test. An out-stretched arm that turns inward and sinks hints at capsule damage.
Babinski plantar reflex. Up-going big toe confirms corticospinal tract hit.
Romberg stance. Sway with eyes closed suggests sensory, cerebellar or proprioceptive failure.
C. Laboratory & pathological tests
Complete blood count (CBC). Detects anaemia, infection or high haematocrit that thickens blood.
Basic metabolic panel. Abnormal sodium or renal failure may mimic or worsen stroke presentations.
Fasting lipid profile. High LDL and low HDL confirm atherosclerotic risk.
HbA1c. Three-month glucose snapshot uncovers occult diabetes.
Coagulation panel (INR, aPTT). Guides thrombolysis safety and unmasks clotting disorders.
High-sensitivity C-reactive protein. Marker of systemic inflammation and atherosclerotic activity.
Erythrocyte sedimentation rate. Elevated rates can point to vasculitis driving perforator occlusion.
Cardiac enzymes (troponin). Rule out silent myocardial infarction occurring alongside stroke.
Plasma homocysteine. High levels stiffen small vessels; corrective folate or B-vitamins can lower risk.
COVID-19 PCR/serology. In pandemic settings, identifies infection that can provoke coagulopathy.
D. Electrodiagnostic and physiologic tests
12-lead ECG. Screens for atrial fibrillation or acute ischaemia.
Continuous cardiac telemetry. Captures paroxysmal AF episodes missed on single ECG.
Transcranial Doppler ultrasound. Measures flow velocity in MCA, detecting micro-embolic signals.
Somatosensory evoked potentials (SSEP). Probes sensory pathway integrity in ambiguous cases.
Electroencephalogram (EEG). Distinguishes post-stroke seizures from new deficits.
E. Imaging tests
Non-contrast CT head. First-line to exclude bleed; early ischaemic change may be subtle.
CT angiography (CTA). Maps MCA stem and detects branch atheromatous plaques.
Diffusion-weighted MRI (DWI). Gold standard—bright “dot” appears within minutes in the deep brain.
Magnetic-resonance angiography (MRA). Visualises vessel lumen without dye; useful for follow-up.
CT perfusion. Colour maps show penumbra vs core even in small strokes.
High-resolution 7-Tesla MRA. Research-grade detail reveals individual lenticulostriate branches and wall thickening. sciencedirect.com
Digital-subtraction angiography (DSA). Invasive but definitive for complex or recurrent cases.
Carotid duplex ultrasound. Looks for upstream plaque that might shower micro-emboli.
Transthoracic echocardiography (TTE). Screens for cardiac clots, septal defects or low ejection fraction.
Transoesophageal echocardiography (TEE). Closer look at left atrial appendage and aortic arch plaques.
PET/CT of cerebral metabolism. Research tool mapping glucose uptake; low uptake confirms irreversible infarct.
SPECT cerebral blood-flow scan. Alternative functional imaging assessing residual perfusion.
Non-Pharmacological Treatments
A. Physiotherapy & Electrotherapy
Early Mobilization: Assisted sitting and standing within 24 h jump-starts circulation, prevents blood clots, and primes neuroplastic rewiring by providing real-world sensory input. Mechanism: activity-dependent cortical remapping. mdpi.com
Passive Range-of-Motion (PROM): Therapist-guided joint movements keep muscles supple and joints lubricated, limiting contractures while afferent input fosters cortical representation.
Task-Specific Training: Practising everyday tasks (buttoning, pouring water) strengthens exactly the neural circuits required for independence.
Constraint-Induced Movement Therapy (CIMT): Immobilising the good arm forces use of the weak arm for 2–6 h/d, driving use-dependent plasticity.
Mirror Therapy: Watching the sound limb in a mirror tricks the brain into thinking the weak limb is moving, activating mirror-neuron networks.
Functional Electrical Stimulation (FES): Surface electrodes trigger wrist-finger extensors during reach-and-grasp, synchronising volition and movement.
Neuromuscular Electrical Stimulation (NMES): Cycled stimulation to antigravity muscles reduces hemiplegic shoulder pain and builds endurance.
Transcutaneous Electrical Nerve Stimulation (TENS): Low-frequency current modulates pain gates and primes sensory cortex for relearning.
Robotic-Assisted Gait Training: Treadmill exoskeletons provide thousands of perfect-form steps, ingraining rhythmic locomotor patterns.
Virtual-Reality (VR) Therapy: Immersive games (e.g., picking fruit) boost motivation while delivering high-dose, multisensory practice.
Balance Platform Training: Real-time visual feedback of centre-of-pressure improves ankle and hip strategies.
Vestibular Rehabilitation: Habituation and gaze-stabilisation drills tame dizziness from brain-stem or parietal damage.
Electromyographic (EMG) Biofeedback: Patients “see” muscle activation on a screen and learn to up- or down-regulate tone.
Aquatic Physiotherapy: Warm-water buoyancy unloads weak limbs; hydrostatic pressure reduces edema and raises core temperature for spasticity relief.
Body-Weight–Supported Treadmill Training: Overhead harness lets very weak patients practise stepping safely, stimulating central pattern generators.
B. Exercise Therapies
Progressive Aerobic Cycling: 20-40 min at 60–80 % peak HR, 3 × wk, improves VO₂ max, cerebral perfusion, and endothelial health.
Resistance Training: 1–3 sets of 8–12 reps, 2 × wk, averts post-stroke sarcopenia and insulin resistance.
Interval Walking Programs: Alternating brisk/slow bouts upregulate BDNF (brain-derived neurotrophic factor).
Tai Chi Chuan: Slow, weight-shifting forms enhance proprioception and lower fall risk.
Pilates-Based Core Work: Mat exercises restore trunk control, key for sitting balance and transfers.
C. Mind-Body Interventions
Mindfulness Meditation: 10–20 min/d lowers cortisol, easing post-stroke anxiety and improving attention.
Guided Imagery: Mentally rehearsing limb movement activates the motor cortex, reinforcing synaptic pathways.
Yoga (Stroke-Adapted): Combines stretching, breath control, and relaxation, reducing spasticity and blood pressure.
Progressive Muscle Relaxation: Systematic tensing/releasing calms sympathetic overdrive, aiding sleep.
Deep Breathing & Resonant Frequency Training: Slows respiration to 6 breaths/min, maximising baroreflex and autonomic balance.
D. Educational & Self-Management Strategies
Stroke-Survivor Schools: Group classes teach risk-factor control, medication adherence, and coping skills.
Goal‐Setting Workbooks: SMART goals with weekly review foster self-efficacy and neuroplastic focus.
Caregiver Skills Training: Hands-on coaching prevents lifting injuries and reduces readmission.
Tele-Rehab Apps: Video-guided home exercises and cloud-logged vitals extend therapy dose beyond clinic walls.
Home-Safety Modification Programs: OT-led assessments add grab bars, remove rugs, and optimise lighting, cutting fall risk by > 30 %. mdpi.compmc.ncbi.nlm.nih.gov
Evidence-Based Drugs
(Always prescribed and timed by qualified clinicians—doses below are adult references)
Alteplase (tPA) 0.9 mg/kg IV (10 % bolus, rest over 60 min) within 4.5 h; dissolves clot by activating plasminogen. Key side effect: brain bleed. ahajournals.org
Tenecteplase 0.25 mg/kg IV push (alt. thrombolytic) may enable faster door-to-needle.
Aspirin 160–325 mg PO within 24 h (if no tPA) then 81 mg/d; antiplatelet, risk: gastritis.
Clopidogrel 75 mg/d PO: P2Y12 blocker; dual therapy with aspirin for 21 days in minor stroke.
Ticagrelor 90 mg BID PO: faster onset, more dyspnoea.
Dipyridamole 200 mg + Aspirin 25 mg BID: inhibits platelet cAMP reuptake.
Atorvastatin 80 mg nightly: high-intensity statin stabilises plaque and promotes endothelial NO.
Rosuvastatin 40 mg nightly: potent LDL-C lowering; caution myalgia.
Apixaban 5 mg BID PO: direct Xa inhibitor for cardio-embolic stroke prevention in non-valvular AF; watch renal function.
Rivaroxaban 20 mg QD: once-daily alternative; risk GI bleed.
Dabigatran 150 mg BID: direct thrombin blocker; antidote idarucizumab.
Warfarin (target INR 2-3): vitamin K antagonist for mechanical-valve AF; numerous food/drug interactions.
Lisinopril 10–40 mg QD: ACE inhibitor lowers BP, limiting recurrent stroke.
Amlodipine 5–10 mg QD: calcium-channel blocker useful in Black or elderly patients.
Hydrochlorothiazide 12.5–25 mg QAM: thiazide diuretic; beware hypokalaemia.
Metformin 500–1000 mg BID: improves insulin sensitivity, indirectly curbing vascular damage in diabetics.
Glyceryl Trinitrate patch 5 mg/24 h: acute BP control in ambulance trials; headache common.
Edaravone 30 mg IV BID (14 days): free-radical scavenger licensed in Asia; side effect: liver enzymes.
Citicoline 500 mg BID PO/IV: enhances phosphatidylcholine synthesis, aiding membrane repair; well tolerated.
Riluzole 50 mg BID: glutamate modulator under study; nausea and dizziness. ahajournals.org
Dietary Molecular Supplements
Omega-3 PUFA (EPA + DHA 2–4 g/d): anti-inflammatory, improves endothelial flow; mechanism—resolvins dampen cytokine storm. ahajournals.org
Vitamin D3 2000 IU/d: boosts neuromuscular function and modulates immune repair via VDR-mediated gene expression.
Curcumin 500 mg BID (with piperine): inhibits NF-κB, reducing post-stroke oedema.
Resveratrol 300 mg/d: sirtuin-1 activator, augments mitochondrial biogenesis.
Coenzyme Q10 200 mg/d: co-factor in electron transport chain, scavenges ROS.
Magnesium citrate 400 mg/d: vasodilator, stabilises NMDA receptors.
L-Carnitine 1–2 g/d: shuttles fatty acids into mitochondria, easing fatigue.
Alpha-Lipoic Acid 600 mg/d: recycles vitamins C & E, improving nerve conduction.
Citicoline (CDP-choline) 500 mg BID: doubles as supplement; supports membrane phospholipids.
Creatine 3 g/d: energy buffer for phosphocreatine shuttle, enhancing rehab tolerance.
Advanced / Regenerative Agents
Note: many remain experimental—offered only in trials or specialised centres
Alendronate 70 mg weekly PO (bisphosphonate): prevents immobility-related osteoporosis, lowering future hip-fracture morbidity.
Zoledronic Acid 5 mg IV yearly: potent anti-resorptive; infusion-related fever possible.
Cerebrolysin 30 mL IV daily × 10–21 days: porcine brain-derived peptide mix promoting neurotrophic signalling and synaptogenesis.
Edaravone (see above) extended regimen: free-radical scavenging neuroprotection.
Granulocyte-Colony Stimulating Factor 5 µg/kg SQ daily × 5: mobilises bone-marrow stem cells to penumbra.
Mesenchymal Stem Cell (MSC) Infusion 1–2 × 10⁶ cells/kg IA/IV: secretes growth factors and can differentiate into astrocytes, enhancing network repair. medicalxpress.comregmednet.com
Umbilical Cord Blood Stem Cells (clinical trial): rich in CD34+ progenitors; delivery by stereotactic injection around lesion cavity.
Hyaluronic Acid Hydrogel Scaffold (viscosupplementation concept): provides 3-D matrix for migrating neuroblasts.
Nerve Growth Factor (NGF) Gene Therapy via viral vector: boosts cholinergic sprouting; risk: fever.
Erythropoietin 33 000 IU IV × 3 doses: anti-apoptotic JAK2/STAT5 activation; monitor HCT to avoid thrombosis.
Surgeries & Procedures
Decompressive Hemicraniectomy: bone flap removal within 48 h of malignant MCA oedema; halves mortality, many survivors achieve mRS ≤ 3. ahajournals.orgpmc.ncbi.nlm.nih.gov
Endovascular Thrombectomy: stent-retriever or aspiration removal of large-vessel clot up to 24 h (DAWN/DEFUSE-3 criteria); restores perfusion instantly.
Carotid Endarterectomy: plaque excision for ≥ 70 % ICA stenosis; prevents recurrent emboli.
Carotid Stenting: less invasive alternative in high-surgical-risk patients.
Extracranial-Intracranial Bypass: superficial temporal artery to MCA graft for chronic perfusion failure.
Ventriculoperitoneal Shunt: diverts CSF in post-stroke hydrocephalus.
Deep Brain Stimulation (DBS) of cerebellar dentate nucleus (trial): modulates motor recovery circuits.
Selective Tendon Lengthening: orthopaedic release of spastic ankle plantarflexors to improve gait.
Implantable FES System: epimysial electrodes wired to pulse generator, allowing hand opening on demand.
Intrathecal Baclofen Pump: precise spasticity control, reducing oral side-effects.
Proven Prevention Steps
Keep blood pressure below 130/80 mm Hg.
Maintain LDL-C < 70 mg/dL with statins.
Stop smoking completely—risk halves in 12 months.
Manage diabetes (HbA1c < 7 %).
Exercise ≥ 150 min moderate-intensity weekly.
Eat a DASH- or Mediterranean-style diet.
Keep BMI 18.5–24.9 kg/m².
Limit alcohol to ≤ 1 (women) or 2 (men) drinks/day.
Treat atrial fibrillation with anticoagulants.
Get annual wellness check-ups to adjust therapies early. ahajournals.org
When to See a Doctor
Immediately (call emergency services) if any new FAST sign—face droop, arm weakness, speech difficulty—or sudden severe headache, vision loss, dizziness, or loss of balance appears.
Within 24 h for transient symptoms (TIA).
Weekly to monthly in the first 6 months post-stroke to titrate blood pressure, cholesterol, glucose meds, and reassess rehab goals.
Long term every 3–6 months for secondary prevention surveillance.
Practical “Do & Avoid” Tips
Do take meds at the same time daily; avoid skipping doses.
Do perform home exercises; avoid prolonged couch time.
Do use assistive devices; avoid unsafe ambulation without support.
Do check skin for pressure sores; avoid sitting > 2 h without shifting.
Do eat colourful fruits/veg; avoid excess salt & trans-fats.
Do hydrate 2 L/day; avoid binge alcohol.
Do keep a stroke symptom card on fridge; avoid shrugging off “funny turns”.
Do practise stress-relief daily; avoid chronic sleep deprivation.
Do schedule vaccine boosters; avoid respiratory infections when possible.
Do involve family in goal-setting; avoid social isolation.
Frequently Asked Questions
1. Can a deep lenticulostriate infarct heal completely?
Yes—because damage is small, many patients regain near-normal strength with early rehab, though fine dexterity may lag.
2. How long does neuroplasticity last?
Fastest in the first 3 months, but meaningful gains can occur up to 2 years with consistent practice.
3. Is tPA safe for seniors?
Age > 80 is no longer an automatic exclusion; benefit often outweighs bleeding risk when treated promptly.
4. What is the time window for mechanical thrombectomy?
Up to 24 h in carefully selected patients with favourable perfusion scans.
5. Does aspirin alone prevent all future strokes?
No—blood-pressure control and statins add more protection than antiplatelet therapy alone.
6. Are statins necessary if cholesterol is ‘normal’?
Yes, high-dose statins stabilise plaque independent of LDL levels after ischemic stroke.
7. Can dietary supplements replace medicines?
No—supplements are adjuncts, not substitutes for evidence-based drugs.
8. Will stem cell therapy be widely available soon?
Phase III trials are ongoing; widespread clinical use is still several years away.
9. Is driving allowed after MCA stroke?
Varies by jurisdiction; usually needs physician clearance and on-road testing after visual-field and cognitive assessment.
10. How can caregivers prevent shoulder pain?
Support the arm during transfers, avoid pulling, and begin gentle range-of-motion from day 1.
11. Are migraines a risk?
Post-stroke central pain and migraine-like headaches can arise; treat early with neurology input.
12. Can I fly after stroke?
Stable patients can fly after 2 weeks, but consult your doctor for DVT-prevention measures.
13. What about pregnancy?
Women should plan pregnancy after vascular risk review; some meds (warfarin, statins) need switching.
14. Do I need lifelong rehab?
Formal therapy may taper, but self-directed exercise and brain-training should continue indefinitely.
15. Where can I find trustworthy resources?
National Stroke Association, AHA/ASA websites, and peer-reviewed journals linked in this article.
Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.
The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members
Last Updated: July 04, 2025.
